Model Medicines
La Jolla, US · Founded 2019 · Delaware corporation · 2 known investors
Model Medicines is an AI-powered biotechnology company that uses computation to discover and engineer small molecule drugs targeting disease-driving biological mechanisms. The company has programs in infectious disease, oncology, and inflammation, with compounds in development including a broad-spectrum antiviral and a BRD4 inhibitor.
AI & Machine LearningBiotechDeep TechDigital Health
Founders & leadership
Model Medicines was founded in 2019 by Daniel Haders.
Investors · 2
Reported raises · per SEC filings
Form D private placements$22.5M disclosed across 4 rounds · 2020–2025
▶$3.3MraisedNov 2025 · 10 investors · OtherRule 506(b)
▶$3.3MraisedNov 2025 · 10 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Daniel HadersExecutive Officer
- Offering amount
- $5M
- Amount sold
- $3.3M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.8MraisedOct 2024 · 43 investors · BiotechnologyRule 506(b)
▶$14.8MraisedOct 2024 · 43 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kip QuackenbushExecutive Officer, Director
- Daniel HadersExecutive Officer, Director
- Marlon EvansExecutive Officer, Director
- Amount sold
- $14.8M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$950KraisedFeb 2024 · 10 investors · BiotechnologyRule 506(b)
▶$950KraisedFeb 2024 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel HadersExecutive Officer, Director
- Marlon EvansExecutive Officer, Director
- Kip QuackenbushExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $950K
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$3.5MraisedNov 2021 · 5 investors · Other TechnologyRule 506(b)
▶$3.5MraisedNov 2021 · 5 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Kip QuackenbushExecutive Officer, Director
- Marlon EvansExecutive Officer, Director
- Daniel HadersExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Model Medicines for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Model Medicines do?
- Model Medicines is an AI-powered biotechnology company that uses computation to discover and engineer small molecule drugs targeting disease-driving biological mechanisms. The company has programs in infectious disease, oncology, and inflammation, with compounds in development including a broad-spectrum antiviral and a BRD4 inhibitor.
- Who founded Model Medicines?
- Model Medicines was founded by Daniel Haders in 2019.
- Who are Model Medicines's investors?
- Model Medicines's investors include 8VC, Particle.
- How much funding has Model Medicines raised?
- Model Medicines has disclosed $22.5M raised across 4 rounds.
- Where is Model Medicines headquartered?
- Model Medicines is headquartered in La Jolla, US.